Treating urinary incontinence using prodrugs of GABA analogs
View Patent ↗Disclosed herein are methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat and/or prevent urinary incontinence in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating and/or preventing urinary incontinence.
1. A method of treating urinary incontinence in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of crystalline 1-{[(α-isobutanoyloxyethoxy)carbonyl]-aminomethyl}-1-cyclohexane acetic acid.
2. A method of treating urinary incontinence in a patient in need of such treatment comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of crystalline 1-{[(α-isobutanoyloxyethoxy)carbonyl]-aminomethyl}-1-cyclohexane acetic acid and a pharmaceutically acceptable cater.
3. The method of claim 1 or claim 2 , wherein the patient is an adult patient and wherein the crystalline 1-{[(α-isobutanoyloxyethoxy)carbonyl]-aminomethyl}-1-cyclohexane acetic acid is administered in an amount of from 300 to 3600 mg gabapentin equivalents/day.
4. The method of claim 1 or claim 2 , wherein the patient is a female patient.
5. The method of claim 4 , wherein the female patient is postmenopausal.
6. The method of claim 5 , wherein menopause is drug induced or surgically induced.
7. The method of claim 1 or claim 2 , wherein the patient is a male patient.
8. The method of claim 1 or claim 2 , wherein the urinary incontinence is drug-induced.
9. The method of claim 1 or claim 2 , wherein the crystalline 1-{[(α-isobutanoyloxyethoxy)carbonyl]-aminomethyl}-1-cyclohexane acetic acid is administered orally.
10. The method of claim 2 , wherein the pharmaceutical composition is a sustained release oral dosage form.
11. The method of claim 10 , wherein the dosage form releases crystalline 1-{[(α-isobutanoyloxyethoxy)carbonyl]-aminomethyl}-1-cyclohexane acetic acid gradually over a period of at least about 6 hours after swallowing the dosage form, thereby providing a therapeutic concentration of gabapentin in the plasma of the patient.
12. The method of claim 10 , wherein the dosage form is an osmotic dosage form, a prodrug-releasing polymer, a prodrug-releasing lipid, a prodrug-releasing wax, tiny timed-release pills or prodrug releasing beads.
13. The method of claim 1 or claim 2 , wherein the urinary incontinence is characterized by symptoms of urge incontinence.
14. The method of claim 1 or claim 2 , wherein the urinary incontinence is characterized by symptoms of stress incontinence.